Marksans Pharma Ltd Share Price – NSE  / BSE

Pharmaceuticals, Small Cap

Marksans Pharma announced that its wholly owned subsidiary Relonchem in UK has received Marketing Authorization for its product Cetirizine Dihydrochloride 1 mg/ml Oral Solution from UK MHRA.

Powered by Capital Market - Live News

The approved product is bioequivalent to the reference listed drug (RLD), Imodium A-D Tablets, 2 mg, marketed by Kenvue Brands LLC (NDA - 019860).

Loperamide Hydrochloride is an anti-diarrheal medication used to manage symptoms of acute and chronic diarrhea, strengthening Marksans Pharma?s portfolio in the US generic pharmaceutical market.

Marksans Pharma is primarily engaged in the business of research, manufacture, marketing and sale of pharmaceutical formulations.

The company?s consolidated net profit rose 1.6% to Rs 98.25 crore on 12.2% jump in revenue from operations to Rs 720.41 crore in Q2 FY26 over Q2 FY25.

Shares of Marksans Pharma fell 1.46% to Rs 189.50 on the BSE.

Powered by Capital Market - Live News

Marksans Pharma announced USFDA final approval of the Company's wholly owned subsidiary Marksans Pharma Inc.'s Abbreviated New Drug Application (ANDA) for Loperamide Hydrochloride Tablets USP, 2 mg (OTC). This product is bioequivalent to the reference listed drug (RLD), Imodium A-D Tablets, 2mg, of Kenvue Brands LLC (Kenvue) NDA - 019860.

 Loperamide Hydrochloride is an anti-diarrheal medication used to control symptoms of acute and chronic diarrhea.

Powered by Capital Market - Live News

Marksans Pharma announced that its wholly owned subsidiary Relonchem in UK has received Marketing Authorization for its following products from UK MHRA:

1. Mefenamic Acid 250 mg Film-Coated Tablets
2. Mefenamic Acid 500 mg Film-Coated Tablets

Powered by Capital Market - Live News